A statement from Diabetes Australia about the withdrawal of Fiasp from the PBS 1 March 2023 Diabetes Australia has been advised that Fiasp insulin will be removed from the Pharmaceutical Benefits Scheme from 1 April 2023. This means people will no longer be able to access it at a subsidised price. Fiasp will be available for people who choose to access it via private prescription; however, this will be more expensive. We understand this is causing distress for some people living with diabetes who currently use this medication. We have conveyed our concerns to Novo Nordisk and the Government, and are continuing these discussions to see what can be done to reduce the impact on people living with diabetes who are using this medication. In the meantime, if you are using Fiasp, we strongly encourage you to make an appointment with your doctor as soon as possible to discuss alternative insulins. If you have any questions or concerns, please contact Diabetes Australia on 1800 177 055.
Media releases 15 May 2024 Diabetes Australia welcomes cost relief in 2024-25 Federal Budget Diabetes Australia welcomes health measures providing cost of living relief in this year's Federal Budget. DA eagerly awaits the outcomes of the current Senate Inquiry into Diabetes. Continue Reading
News 14 May 2024 New PBS listing for treatment of itch associated with chronic kidney disease A new medication has been added to the PBS for people undergoing dialysis and experiencing chronic kidney disease itch. Continue Reading
Blog 13 May 2024 Calls for action on kidney disease screening Dianne Moidin knows better than most about the courage people show when they live with chronic kidney disease. Dianne runs... Continue Reading